ArticleWorld journal of surgical oncology2025
Global, regional, and national burden and trends of prostate cancer in elderly from 1990 to 2021: results from global burden of disease 2021.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost-effectiveness of degarelix versus LHRH agonists in prostate cancer: a systematic review.Frontiers in health services · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEmerging evidence has demonstrated marked geographical and demographic variations in prostate cancer (PC) incidence and mortality rates. As PC predominantly affects the elderly, in-depth analysis of disease trends in this vulnerable population is imperative.
methodsThis study leveraged data from the Global Burden of Disease Study (GBD) 2021 to systematically evaluate temporal trends in the incidence, mortality, and Disability-Adjusted Life Years (DALYs) of PC in elderly aged 70 and above. The analyses were stratified by age group, geographic region, and Socio-demographic Index (SDI) quintiles. Furthermore, this study employed a comprehensive analytical approach, including estimated annual percentage change (EAPC), decomposition analysis, and predictive modeling (Nordpred method).
resultsFrom 1990 to 2021, the burden of PC in elderly exhibited a substantial rise, with incident cases, mortality cases, and DALYs all demonstrating significant increases. In 2021, the global age-standardized rates for incidence (ASIR), mortality (ASMR), and DALYs (ASDALYR) were 348.8 (95% uncertainty interval [UI]: 310.75 to 375.79), 177.93 (95% UI: 152.84 to 194.06) and 2513.84 (95% UI: 2170.81 to 2749.77) per 100,100, respectively. Geographically, the highest persistent burden was observed in High Income North America, Australasia, and high SDI region. Most regions were positively correlated with the SDI. The highest incidences of PC in elderly were in the 95 + age group. Decomposition analysis showed that the increase in burden indicators of PC in elderly globally and in the five SDI regions was mainly caused by population growth. Nordpred analysis predicts slight decline in ASIR, ASMR, and ASDALYR by 2046.
conclusionOur analysis unveils a considerable and relentlessly escalating global PC burden among the elderly, with striking geographical heterogeneity. These data underscore the pressing need for tailored public health strategies to mitigate the burgeoning impact of PC in the worldwide aging populace.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.